Andrx Drops Cardura XL Distribution Deal In Move Away From Brand Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Company moves to terminate a supply and distribution deal with Pfizer because the BPH agent failed to receive FDA approval by Dec. 31, 2004. Andrx is divesting its brand business to focus on its "core competencies" of controlled-release formulation development and distribution.
You may also be interested in...
First Horizon To Promote Fortamet, Altroprev With 100-Rep Sales Force
Andrx divests extended-release metformin and extended-release lovastatin to First Horizon for upfront payment of $50 mil. First Horizon's promotional efforts will focus on growing Fortamet and stabilizing Altoprev's declining market share.
First Horizon To Promote Fortamet, Altroprev With 100-Rep Sales Force
Andrx divests extended-release metformin and extended-release lovastatin to First Horizon for upfront payment of $50 mil. First Horizon's promotional efforts will focus on growing Fortamet and stabilizing Altoprev's declining market share.
Pfizer’s Cardura XL Clears FDA For Benign Prostatic Hyperplasia
The extended-release formulation of doxazosin has a narrower indication than the immediate-release formulation but allows for less frequent dose titration. Both formulations are once-daily.